Patents Issued in June 11, 2020
  • USE OF VALBENAZINE FOR TREATING LEVODOPA-INDUCED DYSKINESIA
    Publication number: 20200179352
    Abstract: Provided herein are methods for treating levodopa-induced dyskinesia by administering to a subject (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester, or an isotopic variant thereof, or a pharmaceutically acceptable salt or polymorph thereof.
    Type: Application
    Filed: April 25, 2018
    Publication date: June 11, 2020
    Inventor: Christopher F. O`Brien
  • MEDICINAL COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY RESPIRATORY DISEASE
    Publication number: 20200179353
    Abstract: A method for treating an inflammatory respiratory disease, comprising administering an effective amount of an RXR agonist represented by formula (1) or (2) as an active ingredient. wherein D, R1, R2, X, Y, Z, R3, R4, X1, Y1, X2, Y2 and Z1 are defined.
    Type: Application
    Filed: September 9, 2016
    Publication date: June 11, 2020
    Applicant: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
    Inventors: Arihiko KANEHIRO, Utako FUJII, Daisuke MORICHIKA, Naohiro ODA, Nobuaki MIYAHARA, Akihiko TANIGUCHI, Hiroki KAKUTA
  • COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER
    Publication number: 20200179354
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Application
    Filed: May 25, 2018
    Publication date: June 11, 2020
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine HOFF, Lars ROSE, Dieter ZOPF, Fabian KIESSLING, Wiltrud LEDERLE, Dennis DOLESCHEL
  • METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE
    Publication number: 20200179355
    Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 11, 2020
    Applicant: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michal GEVA, Ralph LAUFER, Michael HAYDEN, Neta ZACH
  • HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER
    Publication number: 20200179356
    Abstract: The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 11, 2020
    Inventors: Aranapakam M. Venkatesan, Scott K. Thompson, Roger A. Smith, Sanjeeva P. Reddy, Raghava Reddy Kethiri, Purushottam M. Dewang, Gurulingappa Hallur, Chandrika Mulakala
  • TRPA1 ANTAGONISTS FOR TREATMENT OF DRY EYE, OCULAR PAIN AND INFLAMMATION
    Publication number: 20200179357
    Abstract: Stable, clear, ophthalmic formulations and methods of use for an opthalmologically therapeutic effective amount of a TRPA1 antagonist, the formulation comprising buffer system, a viscosity enhancing agent, optionally a preservative, with an opthalmologically acceptable osmolarity and pH, all in an aqueous vehicle. These formulations are effective for treating ocular diseases or conditions caused by, or associated with, or accompanied by ocular pain and inflammatory processes, including, among others, dry eye N disease, uveitis, or any trauma caused by eye surgery or eye injury.
    Type: Application
    Filed: July 6, 2017
    Publication date: June 11, 2020
    Inventors: Jeffrey M. HERZ, Edward A. KESICKI, Charles P. ZUTA
  • COMPOUNDS AND THEIR METHODS OF USE
    Publication number: 20200179358
    Abstract: The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including neurological disorders (e.g., Dravet syndrome, epilepsy), pain, and neuromuscular disorders are also provided herein.
    Type: Application
    Filed: August 15, 2018
    Publication date: June 11, 2020
    Inventors: Kiran Reddy, Gabriel Martinez Botella, Andrew Mark Griffin, Brian Edward Marron
  • METHODS OF TREATING PANCREATIC CANCER
    Publication number: 20200179359
    Abstract: The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
    Type: Application
    Filed: February 14, 2020
    Publication date: June 11, 2020
    Inventors: Petrus Bekker, Shichang MIAO, Israel CHARO, Tom SCHALL
  • DEUTERIUM-ENRICHED PIOGLITAZONE
    Publication number: 20200179360
    Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Application
    Filed: August 5, 2019
    Publication date: June 11, 2020
    Inventor: Anthony W. Czarnik
  • COMPOSITIONS, METHODS OF USE, AND METHODS OF TREATMENT
    Publication number: 20200179361
    Abstract: The present disclosure provides compositions including a ?4?2 nAChR antagonist, pharmaceutical compositions including a ?4?2 nAChR antagonist, methods of making the compositions or pharmaceutical compositions, methods of treatment of a condition (e.g., nicotine addiction) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like. Embodiments of the present disclosure can be used to reduce nicotine cravings and treat nicotine addiction. The compositions have selective affinity for the ?4?2 receptor, which appears to be involved in nicotine dependence.
    Type: Application
    Filed: May 21, 2018
    Publication date: June 11, 2020
    Inventors: Marcello GIULIANOTTI, Lawrence TOLL, Gregory S. WELMAKER, Jinhua WU, Yongping YU
  • DIETARY SUPPLEMENT COMPRISING GLUCURONIDATION INHIBITION ASSIST FOR HEALTHFUL DAILY SYNERGY OF ANTI-INFLAMMATION, CELLULAR ANTI-OXIDANT BOOST, CELLULAR PROTEIN CLEAN-UP BOOST
    Publication number: 20200179362
    Abstract: The present invention comprises a method and system for configuring a dietary supplement and providing same to user, linked to publically accessible notice at least referencing partial autophagy effect. Said dietary supplement can be configured as tablet, capsule, liquid aliquot, powder, pill, food additive or other common or uncommon forms of dietary supplement. Said dietary supplement comprises in recommended daily dose over years, as a majority of milligrams of active ingredients: at least one component to reduce inflammation, at least one component to boost local cellular production of antioxidants, at least one component to boost local cellular clean-up of damaged protein, at least one component to inhibit glucuronidation.
    Type: Application
    Filed: August 21, 2019
    Publication date: June 11, 2020
    Inventor: James E. Beecham
  • METHODS FOR TREATING NASH AND FOR PREVENTING NASH-INDUCED HCC
    Publication number: 20200179363
    Abstract: Disclosed are methods of treating non-alcoholic steatohepatitis (NASH) and methods of preventing NASH-induced hepatocellular carcinoma (HCC), such methods including administering O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime (BGP15), alone or in combination with a inhibitor of the interleukin-6 receptor transsignaling response, particularly gp130Fc.
    Type: Application
    Filed: June 8, 2018
    Publication date: June 11, 2020
    Inventors: Mark Anthony FEBBRAIO, Jozsef MANDL
  • LOW DOSE COMBINATION THERAPY FOR TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
    Publication number: 20200179364
    Abstract: The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a low dose of a Pim inhibitor, N-{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein the combination is unexpectedly synergistic at a very low dose of the Pim inhibitor.
    Type: Application
    Filed: February 6, 2020
    Publication date: June 11, 2020
    Inventors: Holly Koblish, Gary Reuther
  • Method of Regulating Tumor Necrosis Factor-alpha (TNF-alpha) for Treating Cancers, Autoimmune Disorders, and Other Disorders Associated with Chronic Inflammation
    Publication number: 20200179365
    Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
    Type: Application
    Filed: February 10, 2020
    Publication date: June 11, 2020
    Inventor: Jonnie R. Williams
  • METHOD OF TREATING VIRAL INFECTIONS
    Publication number: 20200179366
    Abstract: In one aspect, a method of treating a disorder associated with chronic inflammation includes administering to an individual in need thereof a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In some aspects, the disorder is a cancer, an autoimmune disorder, hypertension, or autism. In other aspects, isomyosmine is administered to treat viral infections or disorders associated with elevated levels of hydrogen peroxide and/or other Reactive Oxygen Species (ROS).
    Type: Application
    Filed: February 14, 2020
    Publication date: June 11, 2020
    Inventor: Jonnie R. Williams
  • Method of Treating Coronavirus
    Publication number: 20200179367
    Abstract: In one aspect, a coronavirus is treated by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, oxidative stress is reduced in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In another aspect, mitochondrial reactive oxygen species (mtROS) are inhibited in an individual suffering from a coronavirus by administering a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof. In one example, the coronavirus is Covid-19.
    Type: Application
    Filed: February 17, 2020
    Publication date: June 11, 2020
    Inventor: Jonnie R. Williams
  • USE OF NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS FOR IMMUNOTHERAPY IN MELANOMA PATIENTS
    Publication number: 20200179368
    Abstract: Disclosed herein are methods and compositions for administering immunotherapy to a subject in need thereof and for treating a subject in need thereof, where in the methods the subject is administered an effective amount of an inhibitor of nNOS for inducing an immunotherapeutic response in the subject and for treating the subject. The disclosed methods and composition may be utilized for treating a subject having a cell proliferative disease or disorder such as melanoma.
    Type: Application
    Filed: December 4, 2019
    Publication date: June 11, 2020
    Applicants: Northwestern University, Chapman University
    Inventors: Richard B. Silverman, Sun Yang
  • TREATMENT OF DIABETIC NEPHROPATHY
    Publication number: 20200179369
    Abstract: The present invention is directed to the treatment of diabetic nephropathy with a) a phosphodiesterase 4 inhibitor, b) a combination of a phosphodiesterase 4 inhibitor with an AT1 angiotensin II receptor antagonist or c) a combination of a phosphodiesterase 4 inhibitor with an angiotensin-converting enzyme inhibitor.
    Type: Application
    Filed: July 28, 2016
    Publication date: June 11, 2020
    Inventors: Guido HANAUER, Stephanie VOLLERT, Masatoshi HAZAMA, Takanori MATSUO
  • TREATMENT OF EPILEPSY
    Publication number: 20200179370
    Abstract: The present invention discloses isoquinolines and 1H-2-Benzopyranes and their use in the treatment and prevention in epilepsy and other seizures. The present invention further discloses methods to screen isoquinoline- and 1H-2-Benzopyran-like molecules as pharmaceutically active compounds.
    Type: Application
    Filed: August 28, 2018
    Publication date: June 11, 2020
    Inventors: Daniëlle COPMANS, Alexander CRAWFORD, Peter DE WITTE, Camila ESGUERRA, Sara KILDGAARD, Thomas OSTENFELD LARSEN, Annelii NY
  • Stabilizing Camptothecin Pharmaceutical Compositions
    Publication number: 20200179371
    Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.
    Type: Application
    Filed: July 12, 2019
    Publication date: June 11, 2020
    Inventors: Daryl C. Drummond, Dmitri B. Kirpotin, Mark Eamon Hayes, Charles Noble, Kevin Kesper, Antoine M. Awad, Douglas J. Moore, Andrew J. O'Brien
  • PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE OF SEBACOYL DINALBUPHINE ESTER
    Publication number: 20200179372
    Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.
    Type: Application
    Filed: December 30, 2019
    Publication date: June 11, 2020
    Inventors: Chan-Jung LI, David Chih-Kuang CHOU, Jin-Ding HUANG, Shin-Jr TSAI, Shu-Wen KUO, Yu-En TIEN
  • PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE OF SEBACOYL DINALBUPHINE ESTER
    Publication number: 20200179373
    Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.
    Type: Application
    Filed: February 18, 2020
    Publication date: June 11, 2020
    Inventors: Chan-Jung LI, David Chih-Kuang CHOU, Jin-Ding HUANG, Shin-Jr TSAI, Shu-Wen KUO, Yu-En TIEN
  • METHODS AND COMPOSITIONS FOR REDUCING TACTILE DYSFUNCTION AND ANXIETY ASSOCIATED WITH AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME
    Publication number: 20200179374
    Abstract: The present invention features a method of reducing tactile dysfunction or anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett Syndrome, or Fragile X syndrome by administering a GABAA agent having reduced blood brain barrier or by expressing a nucleic acid encoding an exogenous alpha or beta subunit of a GABAA receptor in dorsal root ganglion neurons in the subject using a vector.
    Type: Application
    Filed: June 8, 2017
    Publication date: June 11, 2020
    Applicant: President and Fellows of Harvard College
    Inventors: Lauren L. Orefice, David D. Ginty
  • FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES
    Publication number: 20200179375
    Abstract: The invention relates to a pharmaceutical composition comprising a protein phosphatase 2A (PP2A) inhibitor and monosodium glutamate.
    Type: Application
    Filed: December 6, 2019
    Publication date: June 11, 2020
    Inventors: John S. Kovach, Mickey L. Wells
  • NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE
    Publication number: 20200179376
    Abstract: The present invention provides a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof having an inhibitory effect on the production of kynurenine, represented by formula (I): (wherein R6 and R7 may be the same or different and each represent a hydrogen atom or the like, R8, R9, R10, and R11 may be the same or different and each represent a hydrogen atom or the like, R1 represents lower alkyl which may be substituted with cycloalkyl, or the like, and R3 represents optionally substituted aryl or an optionally substituted heterocyclic group).
    Type: Application
    Filed: December 4, 2019
    Publication date: June 11, 2020
    Applicant: Kyowa Kirin Co., Ltd.
    Inventors: Yuichi Fukuda, Toshimi Kanai, Yoshisuke Nakasato, Keisuke Kimpara
  • CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR
    Publication number: 20200179377
    Abstract: Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.
    Type: Application
    Filed: November 8, 2019
    Publication date: June 11, 2020
    Applicant: Hutchison Medipharma Limited
    Inventors: Guangxiu Dai, Hong Jia, Wei-Guo Su
  • Compositions, Devices, and Methods for Treating or Preventing Headaches
    Publication number: 20200179378
    Abstract: Disclosed herein are pharmaceutical compositions, devices, their combinations, and their uses thereof for example in treating or preventing headaches.
    Type: Application
    Filed: December 11, 2019
    Publication date: June 11, 2020
    Inventors: John KOLLINS, Fumiyoshi IWASHIMA, Detlef ALBRECHT, Robert David SCHULTZ
  • INTRANASAL DHE FOR THE TREATMENT OF HEADACHE
    Publication number: 20200179379
    Abstract: Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura.
    Type: Application
    Filed: February 14, 2020
    Publication date: June 11, 2020
    Inventors: Shunji HARUTA, Nikhilesh N. SINGH, John KOLLINS, Salvador RICO
  • SOLUTE AND SOLUTE MIXTURE, AS WELL AS A COMPOSITION COMPRISING AT LEAST ONE SOLUTE, FOR USE IN THE PREVENTION OR TREATMENT OF COSMETIC OR PATHOLOGIC EFFLORESCENCES CAUSED BY AIRBORNE PARTICLES
    Publication number: 20200179380
    Abstract: The invention relates to a compatible solute or a solute mixture, as well as to a composition comprising the solute or solute mixture, for use in the prevention or treatment of cosmetic or pathologic efflorescences caused by airborne particles, such as pigmentation accompanying with skin ageing, and de- or hypopigmentation, hyperpigmentation, as well as alterations accompanying with atrophy in the broadest sense.
    Type: Application
    Filed: February 7, 2020
    Publication date: June 11, 2020
    Applicant: bitop AG
    Inventors: Andreas Bilstein, Jean Krutmann
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATION
    Publication number: 20200179381
    Abstract: There is herein provided an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, as described in the description, for use in treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation, wherein said treatment comprises treating a patient with an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, in a specific manner, and formulations for use or designed for use in such treatments.
    Type: Application
    Filed: April 10, 2017
    Publication date: June 11, 2020
    Inventors: Niklas Bergh, Jonas Faijerson Saljo, Sverker Jern
  • METHODS OF TREATING CIRCADIAN RHYTHM SLEEP DISORDERS
    Publication number: 20200179382
    Abstract: Methods of treating irregular sleep-wake rhythm disorder in subjects and compositions for use in the same are disclosed.
    Type: Application
    Filed: May 11, 2017
    Publication date: June 11, 2020
    Inventors: Carsten T. Beuckmann, Margaret Moline, Andrew Satlin
  • PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS
    Publication number: 20200179383
    Abstract: The present invention relates to phenyl derivatives of formula (I) wherein (R1)a, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description and their use in the treatment of cancer by modulating an immune response comprising a reactivation of the immune system in the tumor. The invention further relates to novel benzofurane and benzothiophene derivatives of formula (III) and their use as pharmaceuticals, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Application
    Filed: May 17, 2018
    Publication date: June 11, 2020
    Inventors: Christoph BOSS, Olivier CORMINBOEUF, Heinz FRETZ, Isabelle LYOTHIER, Davide POZZI, Sylvia RICHARD-BILDSTEIN, Hervé SIENDT, Thierry SIFFERLEN
  • N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER
    Publication number: 20200179384
    Abstract: The present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient. The derivative shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus can be effectively used for the treatment of combination administration.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 11, 2020
    Inventors: Kwangho Lee, Inji Shin, Gildon Choi, Chong Hak Chae, Hyeon Jeong Choe, Myoung Eun Jung, Byeong Uk Jeon, Byoung Chul Cho, Chae Won Park, Hwan Kim, Krishna Babu Duggirala
  • NOVEL COMPOUNDS
    Publication number: 20200179385
    Abstract: The invention provides compounds of formula (I): Said compounds being modulators of Kv3 channels and of use in the prophylaxis or treatment of related disorders.
    Type: Application
    Filed: December 23, 2019
    Publication date: June 11, 2020
    Inventors: Giuseppe ALVARO, Agostino MARASCO
  • METOLAZONE EMULSION FORMULATION
    Publication number: 20200179386
    Abstract: The present invention relates to pharmaceutical formulations comprising metolazone, a lipid, and an emulsifier that provide a lipid formulation of metolazone that can be administered intravenously to patients, thereby enhancing the therapeutic delivery and improving patient care for acute heart failure and resistant edmitious states.
    Type: Application
    Filed: September 11, 2018
    Publication date: June 11, 2020
    Inventor: Somberg John
  • USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS
    Publication number: 20200179387
    Abstract: The present disclosure provides methods of treating and/or preventing osteoporosis using salt-inducible kinase (SIK) inhibitors. Also provided are methods of using SIK inhibitors for increasing the function of osteocytes, increasing the number of osteoblasts, increasing the activity of osteoblasts, inhibiting the resorption of a bone, decreasing the number of osteoclasts, inhibiting the activity of osteoclasts, increasing the mass of a bone, down-regulating the expression of the gene SOST, and/or inhibiting the activity of sclerostin. The SIK inhibitors may be combined with Src inhibitors or CSF I R inhibitors. Exemplary SIK inhibitors include the compounds of the formula: (I), (II), (III), (IV), (V) or (VI).
    Type: Application
    Filed: September 16, 2017
    Publication date: June 11, 2020
    Applicants: The General Hospital Corporation, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Marc Wein, Henry Kronenberg, Thomas Sundberg, Ramnik Xavier, Nathanael S. Gray, Yanke Liang, Hwan Geun Choi, Alykhan Shamji
  • VASODILATORS FOR TREATMENT OF HEART FAILURE
    Publication number: 20200179388
    Abstract: A method for treating or preventing heart failure involving blockage of small blood vessels is described. The method involves administering to a subject in need thereof a therapeutically effective amount of a vasodilator.
    Type: Application
    Filed: April 23, 2018
    Publication date: June 11, 2020
    Inventors: William M. CHILIAN, Vahagn OHANYAN, Liya YIN
  • NOVEL ALK2 INHIBITORS AND METHODS FOR INHIBITING BMP SIGNALING
    Publication number: 20200179389
    Abstract: The present invention provides small-molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to treat subjects with Sjögren's syndrome, or diffuse intrinsic pontine glioma (DIPG).
    Type: Application
    Filed: April 26, 2018
    Publication date: June 11, 2020
    Inventors: Paul B. Yu, Wenwei Huang, Philip Edward Sanderson, Jian-Kang Jiang, Khalida Shamim, Wei Zheng, Xiuli Huang, Gregory Tawa, Arthur Lee, Asaf Alimardanov, Junfeng Huang
  • GONADOTROPIN-RELEASING HORMONE ANTAGONIST DOSING REGIMENS FOR TREATING UTERINE FIBROIDS AND REDUCING MENSTRUAL BLOOD LOSS
    Publication number: 20200179390
    Abstract: The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) antagonist. Suitable GnRH antagonists useful in conjunction with the compositions and methods described herein include thieno[3,4d]pyrimidine derivatives, such as 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxypheny I]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid and the choline salt thereof.
    Type: Application
    Filed: June 5, 2018
    Publication date: June 11, 2020
    Applicant: ObsEva S.A.
    Inventors: Ernest LOUMAYE, Jean-Pierre GOTTELAND, Oliver POHL
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
    Publication number: 20200179391
    Abstract: The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.
    Type: Application
    Filed: February 3, 2020
    Publication date: June 11, 2020
    Inventors: Agnes BIGGART, Fang LIANG, Casey Jacob Nelson MATHISON, Valentina MOLTENI, Advait Suresh NAGLE, Frantisek SUPEK, Vince YEH
  • Idelalisib for Treating Proliferative Vitreoretinopathy and Abnormal Intraocular Neovascularization
    Publication number: 20200179392
    Abstract: Methods using idelalisib to treat proliferative vitreoretinopathy and intraocular pathological angiogenesis (e.g., proliferative diabetic retinopathy (PDR), retinopathy of prematurity (ROP), and wet age-related macular degeneration (AMD)).
    Type: Application
    Filed: August 3, 2017
    Publication date: June 11, 2020
    Applicant: Schepens Eye Research Institute
    Inventor: Hetian LEI
  • COMPOSITIONS AND METHODS FOR AMELIORATING PAIN
    Publication number: 20200179393
    Abstract: This invention is directed to compositions, methods and kits that can be used for the treatment or amelioration of pain.
    Type: Application
    Filed: March 12, 2018
    Publication date: June 11, 2020
    Inventors: Nicolas BAZAN, Hernan BAZAN, Julio ALVAREZ-BUILLA, Dennis PAUL, Carolina BURGOS
  • Compounds that Enhance Atoh1 Expression
    Publication number: 20200179394
    Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
    Type: Application
    Filed: July 22, 2019
    Publication date: June 11, 2020
    Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
  • PHARMACEUTICAL COMPOSITIONS
    Publication number: 20200179395
    Abstract: Pharmaceutical compositions and methods are provided to treat headache, headache-associated symptoms, photophobia, or adverse effects associated with triptan administration.
    Type: Application
    Filed: September 18, 2019
    Publication date: June 11, 2020
    Inventors: Paul Bosse, John Ameling, William Kozarek, Bernard Schachtel
  • PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
    Publication number: 20200179396
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Application
    Filed: February 13, 2020
    Publication date: June 11, 2020
    Inventor: Herriot Tabuteau
  • METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS
    Publication number: 20200179397
    Abstract: In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: December 9, 2019
    Publication date: June 11, 2020
    Inventors: Jian Zuo, Tal Teitz, Jie Fang, Asli Goktug, Taosheng Chen, Jaeki Min, R. Kiplin Guy
  • CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS
    Publication number: 20200179398
    Abstract: The present disclosure relates to methods for treating bronchiectasis, for example, non-cystic fibrosis bronchiectasis with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof, that inhibit dipeptidyl peptidase 1 (DPP1) activity. Methods provided herein are useful for prophylaxis, increasing the lung function in a patient, and/or decreasing the rate of pulmonary exacerbation in a patient. In one embodiment, the compound of Formula (I) is (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide.
    Type: Application
    Filed: July 15, 2019
    Publication date: June 11, 2020
    Inventors: Hans Roland LONN, Stephen CONNOLLY, Steven SWALLOW, Reinilde HEYRMAN, Eugene SULLIVAN, Carlos FERNANDEZ
  • ORAL QUETIAPINE SUSPENSION FORMULATIONS WITH EXTENDED SHELF LIFE AND ENHANCED BIOAVAILABILITY
    Publication number: 20200179399
    Abstract: A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof.
    Type: Application
    Filed: February 6, 2020
    Publication date: June 11, 2020
    Inventors: Carl Tierney, Andrew Gardner, Jan Pick-Katolik, Stacey Powell, Mark Foley, Laurence Ramsey, Andrew Hardeman
  • COMPOSITION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND LATANOPROST
    Publication number: 20200179400
    Abstract: An aqueous composition of latanoprost and SAE-CD is provided. The composition possesses improved stability over otherwise similar compositions excluding SAE-CD. Methods of and systems for treating disease, disorders, conditions or symptoms of the eye that are therapeutically responsive to latanoprost are also provided.
    Type: Application
    Filed: November 1, 2019
    Publication date: June 11, 2020
    Inventors: Naomi Esaki, James D. Pipkin
  • NITRIC OXIDE RELEASING PROSTAGLANDIN DERIVATIVES FOR TREATING NORMAL TENSION GLAUCOMA
    Publication number: 20200179401
    Abstract: This invention provides a method of lowering intraocular pressure in a patient having normal tension glaucoma, comprising contacting an eye of a subject having normal tension glaucoma with a pharmaceutical composition comprising an effective amount of Nitric Oxide releasing prostaglandin derivatives of formula (I).
    Type: Application
    Filed: November 7, 2017
    Publication date: June 11, 2020
    Inventors: Jason Lamar VITTITOW, Megan Elizabeth CAVET